Specificità d'azione dei farmaci antineoplastici

Translated title of the contribution: Specificity of action of anticancer agents

Patrizia Vici, D. Sergi, L. Pizzuti, C. Vincenzoni, E. Vizza, F. Tomao, N. Morace, G. Toglia, E. Mancini, E. Baiocco, L. di Lauro, C. Botti, S. Sindico, M. Lopez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Since the first cancer chemotherapy use, efforts have been made in identifying drugs with an antitumor specific action, but cancer is a very complex situation to be cured with a single agent, and to increase drugs selective cytotoxicity new agent combinations, or innovative cellular cycle related schedule, or the use of pro-drugs have been developed. Notwithstanding some relevant improvements in results, chemotherapy remains often a palliative approach. The improved knowledge of the biology of cancer, and of molecular mechanisms and specific targets, has recently modified the approach to various tumors. In particular, the identification of a single and specific genetic alteration in some tumors such as myeloid chronic leukaemia or gastrointestinal stromal tumors (GIST) led to the development of imatinib, a "target" drug with a multikinase inhibitor activity towards the specific genetic alteration; this unique opportunity is not applicable to other tumors, because usually tumors have multiple genetic alterations with very complex molecular pathways. The development of drugs with a multitarget action is probably the best approach to the majority of human cancers, but other possibility are the combination of multiple agents, each with known selective activity towards a specific molecular target, or the choice of a chemotherapic drug in combination with one or more molecularly targeted drugs. The knowledge of the multiple and extremely complex molecular pathways of the neoplastic cells will hopefully drive oncologic science towards a more "exact" science, with the use of "personalized" treatment in each cancer patient.

Original languageItalian
Pages (from-to)137-149
Number of pages13
JournalClinica Terapeutica
Volume162
Issue number2
Publication statusPublished - 2011

Fingerprint

Antineoplastic Agents
Neoplasms
Pharmaceutical Preparations
Drug Therapy
Gastrointestinal Stromal Tumors
Prodrugs
Drug Combinations
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Molecular Biology
Appointments and Schedules

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Vici, P., Sergi, D., Pizzuti, L., Vincenzoni, C., Vizza, E., Tomao, F., ... Lopez, M. (2011). Specificità d'azione dei farmaci antineoplastici. Clinica Terapeutica, 162(2), 137-149.

Specificità d'azione dei farmaci antineoplastici. / Vici, Patrizia; Sergi, D.; Pizzuti, L.; Vincenzoni, C.; Vizza, E.; Tomao, F.; Morace, N.; Toglia, G.; Mancini, E.; Baiocco, E.; di Lauro, L.; Botti, C.; Sindico, S.; Lopez, M.

In: Clinica Terapeutica, Vol. 162, No. 2, 2011, p. 137-149.

Research output: Contribution to journalArticle

Vici, P, Sergi, D, Pizzuti, L, Vincenzoni, C, Vizza, E, Tomao, F, Morace, N, Toglia, G, Mancini, E, Baiocco, E, di Lauro, L, Botti, C, Sindico, S & Lopez, M 2011, 'Specificità d'azione dei farmaci antineoplastici', Clinica Terapeutica, vol. 162, no. 2, pp. 137-149.
Vici P, Sergi D, Pizzuti L, Vincenzoni C, Vizza E, Tomao F et al. Specificità d'azione dei farmaci antineoplastici. Clinica Terapeutica. 2011;162(2):137-149.
Vici, Patrizia ; Sergi, D. ; Pizzuti, L. ; Vincenzoni, C. ; Vizza, E. ; Tomao, F. ; Morace, N. ; Toglia, G. ; Mancini, E. ; Baiocco, E. ; di Lauro, L. ; Botti, C. ; Sindico, S. ; Lopez, M. / Specificità d'azione dei farmaci antineoplastici. In: Clinica Terapeutica. 2011 ; Vol. 162, No. 2. pp. 137-149.
@article{65bb92f1fc984424bc23257068dfbed0,
title = "Specificit{\`a} d'azione dei farmaci antineoplastici",
abstract = "Since the first cancer chemotherapy use, efforts have been made in identifying drugs with an antitumor specific action, but cancer is a very complex situation to be cured with a single agent, and to increase drugs selective cytotoxicity new agent combinations, or innovative cellular cycle related schedule, or the use of pro-drugs have been developed. Notwithstanding some relevant improvements in results, chemotherapy remains often a palliative approach. The improved knowledge of the biology of cancer, and of molecular mechanisms and specific targets, has recently modified the approach to various tumors. In particular, the identification of a single and specific genetic alteration in some tumors such as myeloid chronic leukaemia or gastrointestinal stromal tumors (GIST) led to the development of imatinib, a {"}target{"} drug with a multikinase inhibitor activity towards the specific genetic alteration; this unique opportunity is not applicable to other tumors, because usually tumors have multiple genetic alterations with very complex molecular pathways. The development of drugs with a multitarget action is probably the best approach to the majority of human cancers, but other possibility are the combination of multiple agents, each with known selective activity towards a specific molecular target, or the choice of a chemotherapic drug in combination with one or more molecularly targeted drugs. The knowledge of the multiple and extremely complex molecular pathways of the neoplastic cells will hopefully drive oncologic science towards a more {"}exact{"} science, with the use of {"}personalized{"} treatment in each cancer patient.",
keywords = "Chemotherapy, Molecular targets, Specificity",
author = "Patrizia Vici and D. Sergi and L. Pizzuti and C. Vincenzoni and E. Vizza and F. Tomao and N. Morace and G. Toglia and E. Mancini and E. Baiocco and {di Lauro}, L. and C. Botti and S. Sindico and M. Lopez",
year = "2011",
language = "Italian",
volume = "162",
pages = "137--149",
journal = "Clinica Terapeutica",
issn = "0009-9074",
publisher = "Societa Editrice Universo",
number = "2",

}

TY - JOUR

T1 - Specificità d'azione dei farmaci antineoplastici

AU - Vici, Patrizia

AU - Sergi, D.

AU - Pizzuti, L.

AU - Vincenzoni, C.

AU - Vizza, E.

AU - Tomao, F.

AU - Morace, N.

AU - Toglia, G.

AU - Mancini, E.

AU - Baiocco, E.

AU - di Lauro, L.

AU - Botti, C.

AU - Sindico, S.

AU - Lopez, M.

PY - 2011

Y1 - 2011

N2 - Since the first cancer chemotherapy use, efforts have been made in identifying drugs with an antitumor specific action, but cancer is a very complex situation to be cured with a single agent, and to increase drugs selective cytotoxicity new agent combinations, or innovative cellular cycle related schedule, or the use of pro-drugs have been developed. Notwithstanding some relevant improvements in results, chemotherapy remains often a palliative approach. The improved knowledge of the biology of cancer, and of molecular mechanisms and specific targets, has recently modified the approach to various tumors. In particular, the identification of a single and specific genetic alteration in some tumors such as myeloid chronic leukaemia or gastrointestinal stromal tumors (GIST) led to the development of imatinib, a "target" drug with a multikinase inhibitor activity towards the specific genetic alteration; this unique opportunity is not applicable to other tumors, because usually tumors have multiple genetic alterations with very complex molecular pathways. The development of drugs with a multitarget action is probably the best approach to the majority of human cancers, but other possibility are the combination of multiple agents, each with known selective activity towards a specific molecular target, or the choice of a chemotherapic drug in combination with one or more molecularly targeted drugs. The knowledge of the multiple and extremely complex molecular pathways of the neoplastic cells will hopefully drive oncologic science towards a more "exact" science, with the use of "personalized" treatment in each cancer patient.

AB - Since the first cancer chemotherapy use, efforts have been made in identifying drugs with an antitumor specific action, but cancer is a very complex situation to be cured with a single agent, and to increase drugs selective cytotoxicity new agent combinations, or innovative cellular cycle related schedule, or the use of pro-drugs have been developed. Notwithstanding some relevant improvements in results, chemotherapy remains often a palliative approach. The improved knowledge of the biology of cancer, and of molecular mechanisms and specific targets, has recently modified the approach to various tumors. In particular, the identification of a single and specific genetic alteration in some tumors such as myeloid chronic leukaemia or gastrointestinal stromal tumors (GIST) led to the development of imatinib, a "target" drug with a multikinase inhibitor activity towards the specific genetic alteration; this unique opportunity is not applicable to other tumors, because usually tumors have multiple genetic alterations with very complex molecular pathways. The development of drugs with a multitarget action is probably the best approach to the majority of human cancers, but other possibility are the combination of multiple agents, each with known selective activity towards a specific molecular target, or the choice of a chemotherapic drug in combination with one or more molecularly targeted drugs. The knowledge of the multiple and extremely complex molecular pathways of the neoplastic cells will hopefully drive oncologic science towards a more "exact" science, with the use of "personalized" treatment in each cancer patient.

KW - Chemotherapy

KW - Molecular targets

KW - Specificity

UR - http://www.scopus.com/inward/record.url?scp=79955628257&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955628257&partnerID=8YFLogxK

M3 - Articolo

VL - 162

SP - 137

EP - 149

JO - Clinica Terapeutica

JF - Clinica Terapeutica

SN - 0009-9074

IS - 2

ER -